share_log

Virpax Pharmaceuticals | 10-K/A: Annual report (Amendment)

Virpax Pharmaceuticals | 10-K/A: Annual report (Amendment)

Virpax製藥 | 10-K/A：年度報表(修正版)
美股SEC公告 ·  2024/10/11 05:11

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals reported a net loss of $15.2 million for fiscal year 2023, compared to $21.7 million in 2022. Total operating expenses decreased to $15.7 million from $21.8 million, with research and development expenses declining 52% to $5.1 million. The company ended the year with $9.1 million in cash.The company reached a settlement agreement with Sorrento Therapeutics and Scilex Pharmaceuticals, agreeing to pay $6 million in cash payments ($3.5 million paid in March 2024 and $2.5 million due by July 1, 2024) plus 6% royalties on future sales of Epoladerm, Probudur and Envelta products. The settlement resolves all claims against Virpax related to the litigation.Management continues to advance its pipeline of non-opioid pain management candidates, though noting substantial doubt about its ability to continue as a going concern due to continuing losses and cash position. The company will need to raise additional capital to fund operations and make the remaining $2.5 million litigation payment. Development activities for Probudur in Israel may face potential delays due to regional conflicts.
Virpax Pharmaceuticals reported a net loss of $15.2 million for fiscal year 2023, compared to $21.7 million in 2022. Total operating expenses decreased to $15.7 million from $21.8 million, with research and development expenses declining 52% to $5.1 million. The company ended the year with $9.1 million in cash.The company reached a settlement agreement with Sorrento Therapeutics and Scilex Pharmaceuticals, agreeing to pay $6 million in cash payments ($3.5 million paid in March 2024 and $2.5 million due by July 1, 2024) plus 6% royalties on future sales of Epoladerm, Probudur and Envelta products. The settlement resolves all claims against Virpax related to the litigation.Management continues to advance its pipeline of non-opioid pain management candidates, though noting substantial doubt about its ability to continue as a going concern due to continuing losses and cash position. The company will need to raise additional capital to fund operations and make the remaining $2.5 million litigation payment. Development activities for Probudur in Israel may face potential delays due to regional conflicts.
Virpax製藥公司報告2023財年淨虧損1520萬美元，較2022年的2170萬美元有所減少。總營業費用從2180萬美元減少至1570萬美元，其中研發費用下降52%，至510萬美元。公司年末現金餘額爲910萬美元。公司與Sorrento Therapeutics和Scilex Pharmaceuticals達成和解協議，同意支付600萬美元的現金款項（350萬美元將在2024年3月支付，250萬美元將在2024年7月1日前到期），並在未來Epoladerm、Probudur和Envelta產品的銷售上支付6%的 royalties。此和解解決了與Virpax相關的所有訴訟索賠。管理層繼續推進其非阿片類疼痛管理候選藥物的研發，但指出由於持續虧損和現金狀況，關於其持續經營能力存在重大疑慮。公司需要籌集額外資金來資助運營並支付剩餘的250萬美元訴訟款項。Probudur在以色列的開發活動可能由於區域衝突而面臨延遲。
Virpax製藥公司報告2023財年淨虧損1520萬美元，較2022年的2170萬美元有所減少。總營業費用從2180萬美元減少至1570萬美元，其中研發費用下降52%，至510萬美元。公司年末現金餘額爲910萬美元。公司與Sorrento Therapeutics和Scilex Pharmaceuticals達成和解協議，同意支付600萬美元的現金款項（350萬美元將在2024年3月支付，250萬美元將在2024年7月1日前到期），並在未來Epoladerm、Probudur和Envelta產品的銷售上支付6%的 royalties。此和解解決了與Virpax相關的所有訴訟索賠。管理層繼續推進其非阿片類疼痛管理候選藥物的研發，但指出由於持續虧損和現金狀況，關於其持續經營能力存在重大疑慮。公司需要籌集額外資金來資助運營並支付剩餘的250萬美元訴訟款項。Probudur在以色列的開發活動可能由於區域衝突而面臨延遲。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Nkarta
    NKTX
    -- 1.970
    Soleno Therapeutics
    SLNO
    -- 67.3900
    NuCana
    NCNA
    -- 1.0700
    ImmunityBio
    IBRX
    -- 3.360
    Marker Therapeutics
    MRKR
    -- 1.3700
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日